JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD Pharm. D V Year PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS Previous Question Paper (April/May - 2019 - R08)

Pharmacoeconomics is the scientific discipline that evaluates the clinical, economic, and humanistic outcomes of pharmaceutical products and services to provide a framework for optimal healthcare resource allocation. It compares the costs (inputs) and consequences (outcomes) of drug therapies.

The need for pharmacoeconomics in the Indian scenario is driven by several critical factors:

• Resource Constraints: India faces significant budgetary limitations in public healthcare, necessitating evidence-based decision-making to ensure that limited funds are spent on the most cost-effective treatments.
• Rising Healthcare Costs: The introduction of high-cost innovative therapies and the increasing burden of chronic diseases necessitate rigorous evaluation of value for money.
• Pricing Policy: Pharmacoeconomic data supports the National Pharmaceutical Pricing Authority (NPPA) in determining fair prices for essential medicines.
• Formulary Management: It assists hospitals and government health programs in selecting drugs for inclusion in essential medicine lists based on clinical efficacy and economic efficiency.
• Health Insurance Expansion: As health insurance penetration grows in India, insurers require economic evidence to determine coverage and reimbursement policies.

Pharmacoeconomic evaluations are systematic methods used to compare the costs and outcomes of two or more healthcare interventions. The primary types include:

• Cost-Minimization Analysis (CMA): Used when two or more interventions have demonstrated equivalent clinical outcomes. The analysis focuses solely on identifying the least expensive option.
• Cost-Effectiveness Analysis (CEA): Compares interventions with different costs and clinical outcomes, where outcomes are measured in natural units (e.g., life-years gained, blood pressure reduction). Results are expressed as an Incremental Cost-Effectiveness Ratio (ICER).
• Cost-Utility Analysis (CUA): A specialized form of CEA that incorporates patient preferences and quality of life. Outcomes are measured in utility-based units, most commonly Quality-Adjusted Life Years (QALYs).
• Cost-Benefit Analysis (CBA): Measures both costs and outcomes in monetary terms. This allows for the calculation of a net benefit or a benefit-to-cost ratio, facilitating comparisons across different sectors of healthcare or beyond.